Equities

ADC Therapeutics SA

ADCT:NYQ

ADC Therapeutics SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.31
  • Today's Change0.10 / 3.12%
  • Shares traded389.38k
  • 1 Year change+330.99%
  • Beta1.5837
Data delayed at least 15 minutes, as of Sep 20 2024 20:15 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy2
Outperform4
Hold1
Sell0
Strong Sell0

Share price forecast in USD

The 5 analysts offering 12 month price targets for ADC Therapeutics SA have a median target of 9.00, with a high estimate of 13.00 and a low estimate of 8.00. The median estimate represents a 180.37% increase from the last price of 3.21.
High305.0%13.00
Med180.4%9.00
Low149.2%8.00

Earnings history & estimates in USD

On Aug 06, 2024, ADC Therapeutics SA reported 2nd quarter 2024 losses of -0.38 per share. This result exceeded the -0.46 consensus loss of the 7 analysts covering the company and exceeded last year's 2nd quarter results by 34.48%.
The next earnings announcement is expected on Nov 08, 2024.
Average growth rate+0.05%
ADC Therapeutics SA reported annual 2023 losses of -2.94 per share on Mar 13, 2024.
Average growth rate+2.12%
More ▼

Revenue history & estimates in USD

ADC Therapeutics SA had 2nd quarter 2024 revenues of 17.41m. This missed the 18.80m consensus estimate of the 7 analysts following the company. This was 8.33% below the prior year's 2nd quarter results.
Average growth rate-1.26%
ADC Therapeutics SA had revenues for the full year 2023 of 69.56m. This was 66.86% below the prior year's results.
Average growth rate+226.01%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.